REG - Physiomics PLC - Notice of AGM

PhysiomicsAnnouncement

17/10/2024 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241017:nRSQ4586Ia&default-theme=true

RNS Number : 4586I  Physiomics PLC  17 October 2024

17 October 2024

 

Physiomics plc

("Physiomics" or the "Company")

 

Notice of AGM

 

 

Physiomics plc (AIM: PYC), a leading mathematical modelling and data science
company supporting the development of new therapeutics and personalised
medicine solutions, is pleased to provide notice of the Company's Annual
General Meeting ("AGM").

 

The AGM will be held at 10.30 a.m. on 19 November 2024 at the Company's
registered office, Bee House, 140 Eastern Avenue, Milton Park, Oxfordshire,
OX14 4SB.

 

Shareholders will shortly be sent either printed copies of the Notice of AGM
and accompanying materials or a letter notifying them that they are available
on the Company's website, depending on the preferences they have expressed to
the Company's registrar.

 

A copy of the Notice of AGM, containing further details of the resolutions to
be proposed at the meeting, as well as a copy of the Company's Annual Report
and Accounts, will be made available today on the Company's website at
www.physiomics.co.uk/investors/corporate-documents/
(http://www.physiomics.co.uk/investors/corporate-documents/) .

 

 

 

Enquiries:

 

Physiomics plc

Dr Peter Sargent, CEO

+44 (0)1235 841575

 

Hybridan LLP (Broker)

Claire Louise Noyce

+44 (0) 203 764 2341

 

Strand Hanson Limited (NOMAD)

James Dance & James Bellman

+44 (0)20 7409 3494

 

 

 

Notes to Editor

 

About Physiomics

 

Physiomics plc combines expertise across Modelling & Simulation,
Biostatistics, Data Science and Bioinformatics, together with deep biology
expertise, to help biotech and pharma companies streamline their drug
development journeys. Our approach is to help derive insight from all relevant
and often disparate data in order to de-risk decision making and optimise
research design across discovery, pre-clinical and clinical studies. Through
use of cutting-edge computational tools, bespoke models and our proprietary
Virtual Tumour technology, the Physiomics team has informed the development of
over 100 commercial projects, with over 125 targets and drugs modelled.
Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics
& CRUK.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOAGZMMGMVDGDZM